Validated UPLC-MS/MS method for the quantification of dasatinib in plasma: Application to pharmacokinetic interaction studies with nutraceuticals in Wistar rats - Fig 1

<p><b>Product ion spectra of DAS, a) and ERL, b)</b>.</p

Main pharmacokinetic parameters (mean±SD) after oral administration of DAS (25 mg/kg) to rats (<i>n</i> = 5).

<p>Main pharmacokinetic parameters (mean±SD) after oral administration of DAS (25 mg/kg) to rats (<i>n</i> = 5).</p

Evaluation of the extraction efficiency and matrix effect for the determination of DAS in rat plasma by the proposed UPLC-MS/MS method.

<p>Evaluation of the extraction efficiency and matrix effect for the determination of DAS in rat plasma by the proposed UPLC-MS/MS method.</p

LC–MS/MS optimized parameters for the determination of the studied drugs.

<p>LC–MS/MS optimized parameters for the determination of the studied drugs.</p

Regression and statistical parameters for the determination of DAS in rat plasma by the proposed UPLC-MS/MS method.

<p>Regression and statistical parameters for the determination of DAS in rat plasma by the proposed UPLC-MS/MS method.</p

Validated UPLC-MS/MS method for the quantification of dasatinib in plasma: Application to pharmacokinetic interaction studies with nutraceuticals in Wistar rats - Fig 3

<p><b>Plasma concentration–time profile of DAS in rats after an oral administration of a combination of DAS (25 mg/kg) following the administration of DAS (25 mg/kg) alone or when co-administered with either curcumin preparations I, II, a), olive oil, I, II, b), or cocoa extract preparations I, II, c)</b>.</p

Evaluation of the intra-day and inter-day accuracy and precision for the determination of DAS in rat plasma by the proposed UPLC-MS/MS method.

<p>Evaluation of the intra-day and inter-day accuracy and precision for the determination of DAS in rat plasma by the proposed UPLC-MS/MS method.</p

Evaluation of the dilution integrity of DAS in rat plasma.

<p>Evaluation of the dilution integrity of DAS in rat plasma.</p